InnoPharmax, Inc.

As of June 30, 2026, InnoPharmax, Inc. carries a market capitalization of 1.33B, placing it among publicly traded companies globally. Its enterprise value stands at 1.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, InnoPharmax, Inc. has 119.58M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, InnoPharmax, Inc. maintains a current ratio of 6.42, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, InnoPharmax, Inc.'s stock has declined approximately 47.47% over the past 52 weeks. The 50-day moving average sits at 10.73, while the 200-day moving average is 13.19.

As of June 30, 2026, InnoPharmax, Inc. holds 263.77M in cash and equivalents against 11.80M in total debt, resulting in a net debt position of -185.79M. Total book value stands at 529.72M, with working capital of 239.39M providing operational flexibility.

InnoPharmax, Inc.'s most recent stock split took place on January 21, 2026 with a 149:150 split ratio.